Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term follow-up of patients with relapsed b-ALL after allo-HSCT treated with CD19 CAR-T cell from recipients and donors

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCan LiuQLQing Li

Discussion

Loading...

Member takes

Overview

Observational analysis shows improved survival in relapsed B-ALL patients post allo-HSCT, indicating donor-derived CAR-T therapy may be advantageous.

Key Points

  • Survival analysis indicated better progression-free survival and overall survival rates in recipient-derived CAR-T cell therapy.
  • The median peak of interleukin-6 was higher in the donor group than that of the recipient group after therapy.
  • Assessment focused on clinical outcomes, donor chimerism, adverse events, and CAR-T cell levels during treatment.
  • Results suggest that recipient-derived CAR-T therapy could be an effective salvage therapy for relapsed B-ALL patients.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e29ahttps://doi.org/10.1182/blood-2025-7670
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting the sanctuary sites: Allogeneic CD19 CAR-T therapy for extramedullary relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation2025
  2. 2Transplantation in combination with CAR T-cell therapy for refractory/relapsed aggressive B-cell lymphoma after failure of CD19 CAR-T cell therapy2025
  3. 3Targeted salvage therapy improves survival in B-ALL relapsing after CD19 CAR-T: A multi-institutional study2025
  4. 4Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia2025
  5. 5Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis2025